☆ 4.7 Article

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

VACCINES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart et al.

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

添加到收藏夹

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

Annika Roessler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Immunology

Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020-October 2021

Eero Poukka et al.

Summary: Recently, the effectiveness of Covid-19 vaccines, especially against mild disease, has decreased due to the emergence of the Delta variant and waning protection. A register-based study in Finland found that the vaccine effectiveness of two-dose mRNA vaccine series against SARS-CoV-2 infection decreased from 82% to 53% after 6 months. Similar trends were observed for other vaccine series. Waning protection was not observed against Covid-19 hospitalization. These results inform decision-making regarding booster doses for healthcare workers.

VACCINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

Ruediger Gross et al.

Summary: According to a study on a cohort of individuals who received heterologous ChAdOx1 nCoV-19 BNT162b2 vaccination, the regimen induced potent humoral and cellular immune responses, with strong neutralization of the most prevalent SARS-CoV-2 variants. The results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern.

EBIOMEDICINE (2022)

添加到收藏夹

Letter Immunology

Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Chloe Dimeglio et al.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Sebastian Havervall et al.

Summary: Emerging data suggests detectable immune responses can last for months after SARS-CoV-2 infection or vaccination, but the degree and duration of protection against reinfection remains uncertain. A study on healthcare workers and COVID-19 patients found that the majority of individuals tested positive for anti-spike IgG antibodies remained positive for at least 8 months, with a significantly reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.

JOURNAL OF INTERNAL MEDICINE (2022)

添加到收藏夹

Article Infectious Diseases

Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021

Ivan Martinez-Baz et al.

EUROSURVEILLANCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination

Bruno Pozzetto et al.

Summary: The study found that a heterologous vaccination regimen using ChAdOx1-S-nCoV-19 and BNT162b2 can provide better protection against SARS-CoV-2 infection with stronger neutralizing activity. This approach can activate memory B cells that recognize SARS-CoV-2, making it suitable for immunocompromised individuals.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

Sara M. Mangsbo et al.

Summary: This study evaluated the specificity and sensitivity of a SARS-CoV-2 IFN-gamma Release Assay (IGRA) using commercially available and in-house designed peptide pools, finding that the in-house generated peptide pool had higher specificity. Sensitivity was higher in a cohort of previously hospitalized COVID-19 patients using the commercially available peptide pools.

PLOS ONE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Sebastian Havervall et al.

Summary: This study found that COVID-19-related symptoms can persist for 8 months among Swedish health care workers, and these symptoms have effects on their home, work, and social functions.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Review Immunology

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2

Tzu-Chuan Ho et al.

Summary: The current findings suggest that heterologous vaccination with ChAdOx1-S and mRNA vaccines can enhance immune responses against SARS-CoV-2, although some recipients may experience a slight decrease in immune responses. Larger scale studies encompassing diverse populations are needed to further assess the effectiveness of this vaccine strategy.

VACCINES (2021)

添加到收藏夹

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

David W. Eyre et al.

Summary: The study found that nearly all healthcare workers develop detectable anti-spike antibodies after receiving the Pfizer-BioNTech or Oxford-AstraZeneca vaccines. Those with prior infection and younger age were more likely to test seropositive after the first dose.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Infectious Diseases

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Annabel A. Powell et al.

Summary: Adults receiving heterologous COVID-19 immunisation with mRNA or adenoviral-vector vaccines had higher reactogenicity rates, especially among those aged over 50, women, and individuals with prior symptomatic/confirmed COVID-19. Those who received heterologous schedules after severe first-dose reactions may have lower reactogenicity after the second dose, depending on the specific combination of vaccines used.

EUROSURVEILLANCE (2021)

添加到收藏夹

Review Immunology

To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination

Nan-Chang Chiu et al.

Summary: The study showed that heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants demonstrated robust immunogenicity and tolerable reactogenicity, along with stronger T cell responses. It suggests that heterologous vaccination is a viable strategy to combat COVID-19, but further research is needed to confirm its benefits and determine the optimal combinations, doses, and intervals.

EXPERT REVIEW OF VACCINES (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

添加到收藏夹

Letter Infectious Diseases

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Matthias Tenbusch et al.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Tina Schmidt et al.

Summary: In healthy adults, vaccination with an mRNA vaccine as a booster, regardless of the initial vaccine, resulted in higher levels of spike-specific antibodies and T cells compared to booster vaccination with ChAdOx1 nCov-19. Heterologous vaccination with ChAdOx1 nCoV-19 followed by an mRNA vaccine induced strong immune responses with acceptable reactogenicity, showing similar or better effects than homologous mRNA vaccine regimens.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

David Hillus et al.

Summary: This study evaluated the reactogenicity and immunogenicity of homologous and heterologous COVID-19 vaccinations, with results showing that heterologous immunization has good immunogenicity and tolerability.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Sebastian Havervall et al.

Summary: The study compared antibody levels in healthcare workers previously infected with SARS-CoV-2 who received a single dose of ChAdOx1 nCoV-19 vaccine and SARS-CoV-2 naive participants who received two doses of BNT162b2 vaccine, finding higher immune response in the former.

EBIOMEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines

Alexandre Vallee et al.

Summary: The study demonstrated robust immune responses after the second dose of heterologous and homologous schedules of ChAdOx1-S and BNT vaccines. Equivalent results were observed after adjustment for covariates, highlighting the importance of flexibility in deploying mRNA and viral vectored vaccines. However, using the ChAdOx1-S schedule vaccination as the heterologous second dose of BNT was associated with decreased IgG antibody levels compared to the homologous BNT/BNT vaccination.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers

Louise Benning et al.

Summary: This study demonstrates that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.

VACCINES (2021)

添加到收藏夹

Article Health Care Sciences & Services

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

Peter Nordstrom et al.

Summary: The study suggests that heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and mRNA vaccines is an effective alternative to increase population immunity against Covid-19, with higher effectiveness compared to homologous vaccination. These findings could have significant implications for vaccination strategies and logistics in the battle against the Covid-19 pandemic.

LANCET REGIONAL HEALTH-EUROPE (2021)

添加到收藏夹

Article Immunology

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients

Renata Varnaite et al.

JOURNAL OF IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden

Ann-Sofie Rudberg et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens

Reinhold Schirmbeck et al.

MOLECULAR THERAPY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.